Weak evidence was found for changes in the genetic and environmental factors underlying ASD and autistic traits over time. Genetic factors played a consistently larger role than environmental factors. Environmental factors are thus unlikely to explain the increase in the prevalence of ASD.

Judge dismisses final claim against scientist’s former employer and curtails lawsuit directed at woman who accused him of sexual harassment

Statistical thinking is a core part of solid, trustworthy biology. However, many studies still include insufficient sample sizes, have poor experimental design or select an incorrect statistical metho...

Heartbeat sound is one of the first rhythmic stimuli encountered by the developing human brain, yet its biological role has remained unexplored. Here we show that heartbeat sound promotes structural a...

Artificial intelligence (AI) and machine learning partnered with big data generation at unprecedented scale is transforming the worlds of biotechnology and pharma, particularly in the arena of drug discovery. From generative AI to unlock novel drug candidates to virtual cells that gleam insights across multimodal biology, we are witnessing the cusp of an exponential curve of AI innovation that is poised to enhance and perhaps overhaul the design and validation of novel therapeutics. In 2024, GEN debuted our virtual summit, The State of AI in Drug Discovery, which drew a record audience. This year’s summit provides a platform for an outstanding group of researchers, evangelists and entrepreneurs to showcase the latest advances, applications and challenges regarding the deployment of AI across therapeutic development. The program features many of the most exciting companies and organizations powering the AI revolution, including NVIDIA, Xaira Therapeutics, Recursion, Chan Zuckerberg Initiative, Arc Institute, Generate: Biomedicines, and more! Please join us on October 29th for a dynamic program featuring: A featured presentation with Bo Wang, PhD (Xaira Therapeutics) on the promise of multimodal AI for health care The democratization of small molecule drug discovery with the developers of Boltz-2, Gabriele Corso, PhD (MIT), Regina Barzilay, PhD (MIT), and Najat Khan, PhD (Recursion) Evolving industry trends across the AI therapeutic landscape with Derek Lowe, PhD (Novartis and author of "In the Pipeline"), Molly Gibson, PhD, (Flagship Pioneering), and Stacie Calad-Thomson, PhD (NVIDIA) Building the virtual cell with Theofanis Karaletsos (Chan Zuckerberg Initiative), Emma Lundberg, PhD (Stanford), Hani Goodarzi, PhD (Arc Institute), and Ron Alfa, MD, PhD (Noetik) What’s next for AI in protein design with Surge Biswas, PhD (Nabla Bio), Tharindi Hapuarachchi, PhD (Generate: Biomedicines), and Oliver Vince, PhD (Basecamp Research) Breakout sessions from our event sponsors, Revvity Signals, Benchling, and Telesis Bio. Registration for The State of AI in Drug Discovery is entirely free. Sponsored by

With the decision, Penn became the third university to decline the offer.

USC interim President Beong-Soo Kim said in a statement that he had sent a letter to the U.S. Department of Education turning down the Trump offer.